| Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic Acid emollient foam in the treatment of patients with atopic dermatitis. | |
| | |
MedLine Citation:
|
PMID: 21637908 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Topical corticosteroids have been the mainstay of treatment for atopic dermatitis (AD) over the last decade, especially in the setting of acute flares. However, heavy and prolonged use of topical corticosteroid is undesirable as it is associated with side effects such as, skin atrophy, telangiectasia, striae, steroid-induced dermatoses, rosacea, acne exacerbation, and in some severe and rare cases, systemic effects such as hypothalamic-pituitary-adrenal axis suppression, growth retardation and ocular problems. Non-steroidal ant-inflammatory agents specific for the treatment of AD (topical calcineurin inhibitors, or TCIs) are now available and they are a viable alternative to topical corticosteroids in treating dermatitis of the face, neck, eyelids, and intertriginous areas where there is a greater risk of the steroid-induced side effects. More recently, medical device emollients have entered the marketplace. These medical devices provide, but are not limited to, anti-oxidant, anti-protease, anti-inflammatory activity, and aid in restoring the natural balance of lipids, which is one of the causes of the epidermal abnormalities seen with AD. The present study evaluated the short-term effectiveness and appeal of a non-steroidal medicated device foam as compared to pimecrolimus cream 1% in the treatment of AD within a wide age group of subjects with active disease at baseline. In this study, both pimecrolimus and the medical device foam exhibited efficacy in mild-to-moderate AD. Primary efficacy was measured by IGA. After four weeks of treatment with the medical device foam, 82% of target lesions were scored "clear" (0) or "almost clear" (1) compared to 71% of target lesions under the pimecrolimus arm. This study confirmed that pimecrolimus cream 1% and the medical device foam work well in the treatment of AD in both adults and children with no associated adverse effects. J Drugs Dermatol. 2011;10(6):666-672. |
| | |
Authors:
|
Amylynne Frankel; Andrew Sohn; Rita V Patel; Mark Lebwohl |
Related Documents
:
|
11190688 - Measuring sound in hospital nurseries. 17268938 - Pharmacy interns on the ward--a pilot study. 10316128 - Growth in medical director numbers continues. 19293118 - Leadership's influence on job satisfaction. 11211278 - A revision of rhizobium frank 1889, with an emended description of the genus, and the i... 14278028 - The use of closed-circuit television for the teaching of psychotherapeutic interviewing... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of drugs in dermatology : JDD Volume: 10 ISSN: 1545-9616 ISO Abbreviation: J Drugs Dermatol Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-06-03 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160020 Medline TA: J Drugs Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 666-72 Citation Subset: IM |
Affiliation:
|
Mount Sinai School of Medicine, Department of Dermatology, New York, NY. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Taurine Chloramine Inhibits NO and TNF-? Production in Zymosan Plus Interferon-? Activated RAW 264.7...
Next Document: A guide to temporal fossa augmentation with small gel particle hyaluronic Acid dermal filler.